Higher concentration insulins: an overview of clinical considerations.

about

Understanding concentrated insulins: a systematic review of randomized controlled trials.Clinical Challenges With Concentrated Insulins: Setting the Record Straight.

P2860

Q47322851-9AA94FF1-F313-40D9-A11E-D5F92EBD3307 Q49899781-4422AF3B-4E85-4C5B-99BD-DBC739A8A4BD

P2860

Higher concentration insulins: an overview of clinical considerations.

Item

http://www.wikidata.org/entity/Q39285855

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Higher concentration insulins: an overview of clinical considerations.

@en

Higher concentration insulins: an overview of clinical considerations.

@nl

type

Item

label

Higher concentration insulins: an overview of clinical considerations.

@en

Higher concentration insulins: an overview of clinical considerations.

@nl

prefLabel

Higher concentration insulins: an overview of clinical considerations.

@en

Higher concentration insulins: an overview of clinical considerations.

@nl

P1476

Higher concentration insulins: an overview of clinical considerations.

@en

P2093

Cynthia Brusko

http://www.w3.org/2001/XMLSchema#string

Fryn Schafer

http://www.w3.org/2001/XMLSchema#string

Timothy S Reid

http://www.w3.org/2001/XMLSchema#string

P2860

New insulin preparations: A primer for the clinician

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).

Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects

Clinical use of U-500 regular insulin: review and meta-analysis.

Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)

The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in i

Attributes Influencing Insulin Pen Preference Among Caregivers and Patients With Diabetes Who Require Greater Than 20 Units of Mealtime Insulin.

Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-ta

P304

554-562

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/00325481.2017.1325311

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

129

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28475455

http://www.w3.org/2001/XMLSchema#string

Higher concentration insulins: an overview of clinical considerations.

about

P2860

P2860

Higher concentration insulins: an overview of clinical considerations.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698